We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medgenics | LSE:MEDU | London | Ordinary Share | COM SHS USD0.0001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 392.50 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
28/6/2012 13:21 | I've never said it will be any price at any time. Retrace hardly a surpise after a 100% rise. You continue to make a fool of yourself IMO. | britishb | |
28/6/2012 12:51 | Anyone know where I can short sell MEDU? I can't with my current online broker. | sueyou1 | |
28/6/2012 12:12 | On the way back to £4 in case you haven't checked the chart lately. Don't worry, it's said by the official US rapmer to be worth £10.8681 within a year. I can think of better investments though, so will be keeping my money there. | sueyou1 | |
27/6/2012 10:09 | sk I think if you read them you'll find my comments are entirely sensible. We just have Sue gone a bit nuts because I questioned the optimism on another thread. Somewhere on this thread you did a very good positive/negative analysis of MEDG/U. As we know lots could go wrong but at least everyone seems to respect the significant risk that this comes to nothing. | britishb | |
27/6/2012 09:23 | kalinit, thanks for your kind comments. I must add that if this personal spat continues, I may have to start moderating this thread. I would rather not, but I will if need be. P.S. Well done to those who have held to these levels. | sicilian_kan | |
27/6/2012 08:42 | SueYou1 and britishb - Gents or Ladies - forgive me but this was a fairly serious forum for serious investors who may/maynot be about to make life changing amounts of money (only time will tell). Posts by Sicilian Khan (see key early research which started this thread) are amongst the best research and balanced comment you will ever find on a BB. Please let us continue to use this BB for what it was designed for, and take your personal feud to another forum, as some of us put a lot of time and effort into what is posted,find it a very useful tool and pay close attention to what is written. It is hard to follow the train of thought, comments and genuine questions when you are both arguing in the way you do. | kalinit | |
26/6/2012 23:56 | 1000 bagger LOL!!!!!!!!!!!!!!!!! More like a paltry 61% gain in the next year SAYS THE EXPERT!!!!!!!!!!!!!! Less than a ONE BAGGER :-)))))))))))))))))) Market Alert: RAY DIRKS Research Wall Street Rumblings Issue LIII May 20, 2012 by Ray Dirks Posted on admin on May 20, 2012 "Medgenics on Thursday announced that it received FDA (Food and Drug Administration) clearance to commence Phase IIb trial of Epodure for sustained anemia treatment in dialysis patients. The stock should sell at $17.00, or 3 times the its current price, within a year." $17 = £ 10.8681 :-)))))))))))))))))) $17 = £ 10.8681 :-)))))))))))))))))) $17 = £ 10.8681 :-)))))))))))))))))) | sueyou1 | |
26/6/2012 23:47 | RAMP! RAMP! RAMP! .... PUMP! PUMP! PUMP! .... DUMP! DUMP! DUMP! (from an unrelated BB, posted by the #1 MEDU ramper) britishb - 26 Jun 2012 - 08:36:01 - 2799 of 2812 Yeah big boy big hitter Matty dude!!!! I see OCDO smashed today. Adding to your collection of laughable stock picks. Of course you sold up yesterday Matty! Yeah, we believe you baby!!!! As for MEDU/MEDG tell me what is wrong with a 10k position (20k as of today btw!!!) in a stock that has potential of 1000 bagging? It's really not my cup of tea (you know I like real profits and real cashflow) but one is allowed to gamble occasionally, non? | sueyou1 | |
26/6/2012 18:46 | Sue, darling. I love you! | britishb | |
26/6/2012 10:48 | lolololol!!!!!!!!!!! Hilarious! | britishb | |
26/6/2012 09:51 | Sadly Sue, as I have pointed out repeatedly, you are IMVHO utterly clueless. Your numbers are utter drivel. There are MEDU and MEDG shares as well as MDGN in the US. Market cap is way higher than you suggest. Did you read the thread header? "At the ProActive presentation on 23 June 2011, the Medgenics' CEO Andy Pearlman stated that Isaac Blech believes that Medgenics could become the next Genentech. Isaac Blech has founded 7 biotech companies that now have a combined value of more than $30bn. Isaac Blech is one of the leading biotechnology entrepreneurs and investors in the US. He has now bought 17.5% of Medgenics and has just been appointed to the board of directors." So, one of the world's leading biotech investors bought 17.5% of the company. Genentech, just for your info, was sold to Roche for $46.8 billion. Tell me, just how many more times are you going to embarrass yourself? | britishb | |
26/6/2012 09:42 | I've read every post on this thread Sue. One of the better ones and I think just about everyone can see that there's massive potential as well as a very good chance that the MEDG story will come to nothing. What's your point? | britishb | |
26/6/2012 09:33 | Anyone looking at QFI? Some poster called Britishb says they beat MEDU as they are going to be a 1000+ bagger! | sueyou1 | |
25/6/2012 20:00 | So taking those slightly old figures: idix at 1 billion plays medu at 69 million = 14 times our mkt cap achn at 471 mn = 6.8 times our mkt cap | andrbea | |
25/6/2012 16:12 | Not in these, but bet the guys who were saying P&D feel utterly sick. | mustau | |
25/6/2012 15:50 | looking good andrbea much more to come | jammytass | |
25/6/2012 15:19 | Medgenics regulatory advisor Marlene Haffner added that the device "potentially offers significant advance over current treatment not just for an orphan disease, but also for other diseases where protein therapy is a potential treatment," such as multiple sclerosis, arthritis, paediatric growth hormone deficiency, obesity and diabetes. The company has said it plans to develop and/or out-license a pipeline of future Biopump products targeting the protein therapy market, which is forecast to reach $132 billion in 2013. | andrbea | |
25/6/2012 15:06 | Medgenics, Inc. (NASDAQ:MDGN) surged on word of a continued FDA orphan drug status. Shares were up 13% at $10.00 on over 200,000 shares right before the closing bell, a $6.00 stock Tuesday | andrbea | |
21/6/2012 19:00 | Market cap at the 540p buy price when fully diluted is now around £105,000,000. | sicilian_kan | |
21/6/2012 15:45 | At 530p and I'm back in profit at last. Good luck to all holders lets hope we are close to 'lift off' as JT put it. | count chris |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions